Comparing Oral vs. Injectable Semaglutide: Is One More Effective Than the Other?
It’s hard to watch the news or scroll through social media without encountering stories about weight loss drugs like ...
TipRanks on MSN4h
iX Biopharma’s iXB 401: A Breakthrough in Drug Delivery
X Biopharma Ltd. (SG:42C) has released an update. iX Biopharma Ltd. announced that its novel semaglutide sublingual wafer, iXB 401, achieved 20 ...
Medpage Today on MSN17h
Over 50% of U.S. Adults Qualify for Ozempic, Wegovy
More than half of all adults in the U.S. are eligible for semaglutide (Ozempic, Wegovy, Rybelsus), researchers estimated.
T-Net2d
Lexaria Receives Ethics Board Approval for 12-Week Phase 1b DehydraTECH GLP-1 Study in Diabetes and Weight Loss
Ethics Board Approval Granted for Lexaria Receives Ethics Board Approval for 12-Week Phase 1b DehydraTECH GLP-1 Study in ...
Lexaria Bioscience Corp.: Ethics Board Approval Granted for Lexaria's 12-Week Phase 1b DehydraTECH GLP-1 Study in Diabetes and Weight Loss
DehydraTECH clinical test article manufacturing has been completed KELOWNA, BC / ACCESSWIRE / November 13, 2024 / Lexaria Bioscience Corp. (Nasdaq:LEXX, LEXXW) (the "Company" or "Lexaria"), a global i ...
Ethics Board Approval Granted for Lexaria's 12-Week Phase 1b DehydraTECH GLP-1 Study in Diabetes and Weight Loss
The Company is also announcing that clinical test article manufacturing for all planned Study arms has already been completed. This includes production for the four planned DehydraTECH formulation ...
Lexaria Bioscience signs contract for DehydraTECH GLP-1 biodistribution study
Lexaria Bioscience (LEXX) has engaged a contract research organization to perform the world’s first-ever fluorescently tagged ...
Lexaria Signs Contract For New DehydraTECH GLP-1 Biodistribution Study
World's First-Ever Study Tracking Biodistribution of DehydraTECH GLP-1 Molecules KELOWNA, BRITISH COLUMBIA / ACCESSWIRE / ...
Yahoo6d
The Woman’s World Expert-Reviewed Glossary of GLP-1, Semaglutide and Telehealth
Rybelsus: Novo Nordisk’s name-brand version of oral semaglutide tablets to help improve blood sugar levels (along with diet ...
Zacks.com on MSN4d
Amgen Shrugs Off Bone Density Concerns Related to Obesity Candidate
Amgen refutes in a press release that its trial obesity drug, MariTide, may cause bone loss density. Amgen's stock has risen 4.6% this year against a decrease of 3.8% for the pharmaceuticals industry.